Examines patient satisfaction with ravulizumab treatment in generalized myasthenia gravis, indicating important quality of life factors.
To understand the real-world patient experience with ravulizumab, including health-related quality of life (HR-QoL) and other disease-related impacts, and to determine key drivers of the ravulizumab treatment experience using a patient satisfaction survey.
No takes yet. Share an insight, caveat, or question.
Shugars et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: